Search This Blog

Thursday, November 19, 2020

Jobless claims rise; COVID-19 surge seen slowing labor market healing

 

The number of Americans filing first-time claims for jobless benefits unexpectedly rose last week, likely as new business restrictions to control spiraling COVID-19 infections unleashed a fresh wave of layoffs, which could further slow the labour market recovery.

The weekly unemployment claims report from the Labor Department on Thursday, the most timely data on the economy's health, also showed at least 20.3 million people on unemployment benefits at the end of October, seven months after the pandemic started in the United States.

Millions will lose benefits next month when two government-funded programs expire. President-elect Joe Biden will inherit the public health crisis and a frail economy when he takes over from President Donald Trump on Jan. 20.

Initial claims for state unemployment benefits increased 31,000 to a seasonally adjusted 742,000 for the week ended Nov. 14. Economists polled by Reuters had forecast 707,000 applications for the latest week.

Unadjusted claims rose 18,344 to 743,460 last week. Economists prefer the unadjusted number given earlier difficulties adjusting the claims data for seasonal fluctuations because of the economic shock caused by the pandemic. Including a government-funded program for the self-employed, gig workers and others who do not qualify for the regular state unemployment programs, 1.1 million people filed claims last week.

Daily new COVID-19 cases in the United States have been exceeding 100,000 since early this month, pushing the number of infections in the country above 11 million, according to a Reuters tally. Forty-one states have reported daily record increases in coronavirus infections and 20 have registered new all-time highs in coronavirus-related deaths from day to day. The death toll in the United States has surpassed 250,000.

Many jurisdictions have imposed restrictions on businesses to try to contain the spread of the virus.

Wall Street's main indexes opened lower due to the soaring COVID-19 cases and rise in weekly jobless claims. The dollar rose against a basket of currencies. U.S. Treasury prices were higher.

RECOVERY SLOWING

Unemployment claims dropped from a record 6.867 million in March as about 80% of the people temporarily laid off in March and April were rehired. That accounted for most of the rebound in job growth over the last six months.

Raging coronavirus infections and restrictions will weigh heavily on bars and restaurants as well as other businesses in the services sector that attract crowds.

The resurgence in COVID-19 cases coincides with the end of more than $3 trillion in government pandemic relief for businesses and workers, which helped to preserve jobs and lift the economy of the depths of the worst recession since the Great Depression.

In addition to a weekly unemployment subsidy, which has mostly expired, the government-funded program for people who do not qualify for regular state unemployment and another for those who have exhausted their six months of eligibility will lapse in December, creating what economists have called an income cliff.

Claims remain above their 665,000 peak during the 2007-2009 Great Recession. The claims data covered the period that the government surveyed businesses for the nonfarm payrolls portion of November's employment report.

The government reported early this month that nonfarm payrolls increased by 638,000 jobs in October, the smallest gain since the jobs recovery started in May. That followed 672,000 jobs added in September. Only 12.1 million of the 22.2 million jobs lost in March and April have been recovered.

Though the claims report showed a decline in the number of people on unemployment rolls in early November, that was because many people have exhausted their eligibility for benefits, which are limited to six months in most states.

The number of people receiving benefits after an initial week of aid declined 429,000 to 6.372 million in the week ending Nov. 7. A record 4.377 million workers filed for extended unemployment benefits in the week ending Oct. 31, up 233,458 from the prior week. There were 20.3 million people collecting unemployment checks at the end of October under all programs.

https://www.marketscreener.com/news/latest/U-S-weekly-jobless-claims-rise-COVID-19-surge-seen-slowing-labour-market-healing--31820999/

Lilly, Ypsomed collaborate on automated insulin delivery system in diabetes

 

  • Eli Lilly (NYSE:LLY) and Ypsomed (OTC:YPHDF) announce a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly's connected diabetes solutions.
  • Under the terms of agreement, Lilly will commercialize the system, currently in development and will include an insulin pump developed and manufactured by Ypsomed.
  • Ypsomed's insulin pump has been marketed in Europe since 2016. Available in 21 countries as the mylife YpsoPump, this pump stands out for its small size and its unique, icon-based touch screen.
  • Lilly will commercialize a version of this insulin pump, along with continuous glucose monitoring in the U.S. and Europe. This pump will use pre-filled insulin cartridges for Lilly's rapid-acting insulins.
  • Ypsomed plans to submit mylife YpsoPump for FDA clearance for use in automated insulin delivery in 2022. If cleared, Lilly will have exclusive rights to commercialize the pump in the U.S.
  • https://seekingalpha.com/news/3637853-lilly-and-ypsomed-collaborate-to-advance-automated-insulin-delivery-system-in-diabetes

VBI Vaccines up after VBI-1901 data in early-stage brain cancer study

 

  • VBI Vaccines (NASDAQ:VBIV) rises 4% in premarket, after announcing data from Phase 2a (Part B) from its ongoing Phase 1/2a study evaluating its cancer vaccine candidate, VBI-1901, designed to target cytomegalovirus (CMV) as a foreign viral antigen in recurrent glioblastoma (GBM), an aggressive form of cancer that occurs in brain or spinal cord.
  • Interim data showed 2 partial responses and 2 stable disease in the VBI-1901 + GM-CSF vaccinated group, resulting in a disease control rate of 40% (n=4/10).
  • 56% disease control rate achieved in the group vaccinated with VBI-1901 combined with GSK’s adjuvant AS01, with 5 stable disease observations (n=5/9);tumor response data for the 10th patient enrolled is pending.
  • Presumed pseudoprogression was observed in both vaccinated groups– defined as immune infiltration into the tumor which appears initially as tumor growth, but later subsides resulting in tumor growth stabilization and/or shrinkage.
  • On the safety front, VBI-1901 was well-tolerated with both adjuvants, and no safety signals observed in either vaccinated group.
  • VBI is exploring a potential registration study, for the next phase of development, which could begin in 2021.
  • https://seekingalpha.com/news/3637918-vbi-vaccinesplus-4-after-vbiminus-1901-data-in-early-stage-brain-cancer-study

XBiotech's flu-COVID-19 therapeutic cocktail shows effective anti-virus activity

 

  • XBiotech (NASDAQ:XBIT) announces new data for its candidate therapy for treating infections of influenza and COVID-19. The Company continues to analyze components of its FLUVID therapy.
  • The True Human antibodies targeting the virus causing COVID-19 were found to effectively neutralize a test virus about four-times better than the antibodies the FDA is now considering for emergency use authorization.
  • Ongoing research has also found that the True Human antibodies in this therapeutic cocktail are capable of rescuing 100% of animals that receive an otherwise lethal dose of flu virus.
  • The latest research findings suggest the FLUVID therapy, could provide effective therapy for treating complex infections from one or more of these viruses.
  • There is no other therapy available to treat both COVID-19 and Influenza infections that occur together.
  • https://seekingalpha.com/news/3637928-xbiotechs-influenza-covidminus-19-therapeutic-cocktail-shows-effective-anti-virus-activity

GoodRX rallies after CEO shrugs off Amazon threat

 

Biopharma SPAC Jiya Acquisition prices $100M IPO

 

AstraZeneca-Oxford vax produces strong immune response in older adults

 

  • Vaccine optimism continues after a jab from the University of Oxford, which is working in collaboration with AstaZeneca (NASDAQ:AZN), was shown to have generated a robust immune response in adults in their 60s and 70s.
  • Preliminary results revealed that the vaccine, ChAdOx1 nCoV-19, prompted what's known as a "T-cell response" within 14 days of the first dose, as well as an antibody response within 28 days of a booster dose.
  • "The populations at greatest risk of serious COVID-19 disease include people with existing health conditions and older adults," said Dr. Maheshi Ramasamy, a co-author of the study at the University of Oxford. "We hope that this means our vaccine will help to protect some of the most vulnerable people in society, but further research will be needed before we can be sure."
  • Phase three trials of the vaccine are still ongoing, with early efficacy readings possible in the coming weeks. Earlier data from a vaccine developed by Pfizer and BioNTech showed an efficacy rate of 95%, with 94% effectiveness in those aged 65 and over.
  • This news about AstaZeneca's (AZN) COVID-19 vaccine follows positive news about vaccines from Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA). However, the stock market reaction to the positive news about COVID vaccines has been negative, suggesting that vaccine enthusiasm may be priced in.
  • BofA's Michael Hartnett even suggests that investors should 'Sell the vaccine'.
  • https://seekingalpha.com/news/3637787-vaccine-from-astrazeneca-oxford-produces-strong-immune-response-in-older-adults